Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MATAO maintenance letrozole trial in ER-positive epithelial ovarian cancer
2019-002264-27Phase 3Active
- Sponsor
- Swiss GO Trial Group
- Start
- Jan 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) comparing Letrozole maintenance with Placebo maintenance (2 arms). Primary endpoint: Progression-Free Survival. Started Jan 2021; status: active.
02
Drugs
letrozole
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on 2019-002264-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002264-27.